A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Study Identifier
M14-172
CT.gov Identifier
NCT02642432
EudraCT Identifier
2015-003797-32
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Hepatitis
  • Cirrhosis
    • Study Drug
  • ABT-493/ABT-530
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Screening laboratory result indicating hepatitis C virus (HCV) Genotype 1, 2, 4, 5 or 6 (GT1,2,4,5,6) infection * Chronic HCV infection * Subject must be HCV treatment-naïve or have failed prior HCV treatment * Subject must have documented compensated cirrhosis and no current or past clinical evidence of decompensated liver disease
    Exclusion Criteria:
    * Positive test result at screening for Hepatitis B surface antigen or anti-human immunodeficiency virus (anti-HIV) antibody * HCV genotype performed during screening indicating co-infection with more than 1 HCV genotype * Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT-493/ABT-530

    Protocol Summary

    The purpose of this study is to assess the safety and efficacy of ABT-493/ABT-530 following 12 weeks of treatment in adults with chronic Hepatitis C Virus Infection genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis.

    Study Locations

    No locations found.